Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MOGAT2 | Q3SYC2 | 3/20 | 0.53 |
| ▸ | CNR2 | P34972 | 12/20 | 0.52 |
| ▸ | MGAT2 | Q10469 | 1/20 | 0.47 |
| ▸ | DRD4 | P21917 | 5/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL324519 | 0.88 | CNR2 (0.58) | MOGAT2CNR2MGAT2DRD4 | |
| SCHEMBL323232 | 0.88 | CNR2 (0.59) | MOGAT2CNR2MGAT2DRD4 | |
| SCHEMBL326462 | 0.85 | MEN1 (0.46) | MOGAT2CNR2 | |
| Hydrochloric Acid SCHEMBL322877 | 0.84 | KMT2A (0.47) | MOGAT2CNR2 | |
| SCHEMBL1627291 | 0.83 | CNR2 (0.66) | MOGAT2CNR2MGAT2 | |
| SCHEMBL323536 | 0.83 | CNR2 (0.59) | MOGAT2CNR2MGAT2DRD4 | |
| SCHEMBL323233 | 0.81 | CNR2 (0.48) | MOGAT2CNR2DRD4CYP1A2CYP3A4 | |
| SCHEMBL323965 | 0.80 | MEN1 (0.41) | MOGAT2CNR2 | |
| SCHEMBL323226 | 0.80 | CNR2 (0.53) | MOGAT2CNR2DRD4CYP1A2CYP3A4 | |
| SCHEMBL27405274 | 0.79 | CNR2 (0.77) | MOGAT2CNR2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9662337-B2 | Bisaryl (thio)morpholine derivatives as S1P modulators | ABBVIE B.V. (NL) | 2017-05-30 | — | — | US | disclosed |
| US-9662337-B2 | Bisaryl (thio)morpholine derivatives as S1P modulators | ABBVIE B.V. (NL) | 2017-05-30 | — | — | US | disclosed |
| US-9662337-B2 | Bisaryl (thio)morpholine derivatives as S1P modulators | ABBVIE B.V. (NL) | 2017-05-30 | — | — | US | disclosed |
| US-20160151376-A1 | BISARYL (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS | ABBVIE B.V. (NL) | 2016-06-02 | — | — | US | disclosed |
| US-20160151376-A1 | BISARYL (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS | ABBVIE B.V. (NL) | 2016-06-02 | — | — | US | disclosed |
| US-20160151376-A1 | BISARYL (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS | ABBVIE B.V. (NL) | 2016-06-02 | — | — | US | disclosed |
| EP-2590954-B1 | BISARYL (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS | ABBVIE BV (NL) | 2016-04-13 | — | — | EP | disclosed |
| EP-2590954-B1 | BISARYL (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS | ABBVIE BV (NL) | 2016-04-13 | — | — | EP | disclosed |
| US-9227960-B2 | Bisaryl (thio)morpholine derivatives as S1P modulators | ABBVIE B.V. (NL) | 2016-01-05 | — | — | US | disclosed |
| US-9227960-B2 | Bisaryl (thio)morpholine derivatives as S1P modulators | ABBVIE B.V. (NL) | 2016-01-05 | — | — | US | disclosed |
| US-20150191457-A1 | BISARYL (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS | ABBVIE B.V. (NL) | 2015-07-09 | — | — | US | disclosed |
| US-9029371-B2 | Bisaryl (thio)morpholine derivatives as S1P modulators | ABBVIE B.V. (NL) | 2015-05-12 | — | — | US | disclosed |
| US-9029371-B2 | Bisaryl (thio)morpholine derivatives as S1P modulators | ABBVIE B.V. (NL) | 2015-05-12 | — | — | US | disclosed |
| US-9029371-B2 | Bisaryl (thio)morpholine derivatives as S1P modulators | ABBVIE B.V. (NL) | 2015-05-12 | — | — | US | disclosed |
| US-20130203745-A1 | BISARYL (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS | ABBVIE B.V. (NL) | 2013-08-08 | — | — | US | disclosed |
| US-20130203745-A1 | BISARYL (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS | ABBVIE B.V. (NL) | 2013-08-08 | — | — | US | disclosed |
| US-20130203745-A1 | BISARYL (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS | ABBVIE B.V. (NL) | 2013-08-08 | — | — | US | disclosed |
| EP-2590954-A1 | BISARYL (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS | ABBVIE B.V. (NL) | 2013-05-15 | — | — | EP | disclosed |
| WO-2012004375-A1 | BISARYL (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS | ABBOTT HEALTHCARE PRODUCTS B.V. (NL) | 2012-01-12 | — | — | WO | disclosed |
| WO-2012004375-A1 | BISARYL (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS | ABBOTT HEALTHCARE PRODUCTS B.V. (NL) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130203745-A1 | BISARYL (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS | S1PR3, S1PR1, S1PR2 | MOGAT2 1415/4885CNR2 9/4885MGAT2 3133/4885 |
| US-20150191457-A1 | BISARYL (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS | S1PR3, S1PR1, S1PR2 | MOGAT2 1281/4885CNR2 9/4885MGAT2 3118/4885 |
| US-20160151376-A1 | BISARYL (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS | S1PR1, S1PR3, S1PR2 | MOGAT2 1234/4885CNR2 25/4885MGAT2 2443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.